Helicobacter pylori seropositivity is associated with enhanced platelet activation in patients with intermittent claudication  by Cassar, Kevin et al.
Helicobacter pylori seropositivity is associated with
enhanced platelet activation in patients with
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Objective: Patients with intermittent claudication have a significantly increased risk of mortality from cardiovascular and
cerebrovascular causes. Helicobacter pylori infection and abnormal platelet function have been shown to be associated with
atherosclerosis as well as with acute ischemic events. The aim of this study was to assess for the first time the relation
between H pylori serology status, platelet activation, and endothelial injury in patients with intermittent claudication.
Design of study : A prospective observational study of 125 patients with intermittent claudication suitable for angioplasty
was conducted at the Vascular Unit of the Aberdeen Royal Infirmary.
Main outcome measures: Main outcome measures were (1) H pylori serology using ELISA kit for immunoglobulin G
antibody to H pylori and (2) whole blood flow cytometric analysis of resting platelet P-selectin expression and fibrinogen
binding as measures of platelet activation. Results are presented as platelet percentage. von Wildebrand factor levels were
measured using ELISA as a marker of endothelial injury. Carstair deprivation scores were calculated for all patients.
Results: H pylori serology was positive in 62 patients (49.6%), negative in 56 (44.8%) and equivocal in 7 (5.6%). Median
P-selectin expression was significantly increased in H pylori–positive patients compared with seronegative patients (0.815
vs 0.65; P  .039). Median platelet fibrinogen binding was higher in seropositive patients, but this failed to reach
statistical significance (2.135 vs 1.85%; P .11). There was no difference in von Wildebrand factor levels between the two
groups (P  .51). There was no difference in socioeconomic status between the two groups.
Conclusion: Patients with intermittent claudication who are H pylori positive show enhanced platelet activation that does
not appear to be mediated by means of endothelial cell injury. (J Vasc Surg 2004;39:560-4.)
Intermittent claudication carries a significantly in-
creased risk of mortality from cardiovascular and cerebro-
vascular events.1,2 Platelet adhesion, activation, and aggre-
gation play a central role in these ischemic events, and
platelet activation has been shown to be enhanced in this
group of patients.3 Arterial vessel wall injury and the asso-
ciated inflammatory response are considered to play an
important role in the development and progression of
atherosclerosis.4-7
There is mounting evidence that certain infectious
agents can trigger endothelial injury and the subsequent
changes leading to atherosclerosis.8-10 Previous infection
with Helicobacter pylori has been shown to be associated
with the presence of atherosclerosis in the coronary, ca-
rotid, or peripheral vessels. H pylori DNA has been identi-
fied within atherosclerotic plaques from the carotid11,12
and coronary arteries,11,13,14 as well as from the aorta11 but
not in healthy arteries. The prevalence of H pylori seropos-
itivity is significantly higher in patients with ischemic heart
disease, peripheral arterial disease, and cerebrovascular dis-
ease compared with control subjects.8,15,16 Kahan et al16
calculated the odds ratio of patients who were positive for
H pylori for developing a myocardial infarction at 1.36
compared with seronegative subjects. Similarly the odds
ratio for lacunar stroke associated with H pylori seropositiv-
ity was 2.21.15
It is not yet clear whether the relation between H pylori
and atherosclerosis is a causal one. It has been hypothesized
that H pylori could be associated with one of the conven-
tional risk factors for atherosclerosis and that H pylori is,
therefore, only indirectly linked to atherosclerosis. How-
ever, in a meta-analysis that involved more than 10,000
patients no such association has been demonstrated.17
Various mechanisms through which H pylori could
exert an effect have been proposed. Direct endothelial
injury by the microorganism has been identified as one
possible link to atherogenesis.9 Another possible mecha-
nism of action is cross-reactivity of H pylori antibodies with
both healthy and atherosclerotic blood vessels,18resulting
in endothelial injury. This injury would be expected to lead
to platelet adhesion and activation which, in turn, play an
important role in the development and progression of
atherosclerosis. Platelets also play a pivotal role in acute
events such as myocardial infarction and ischemic stroke
with which H pylori has also been associated.
Both H pylori seropositivity and platelet activation are
increased in patients with peripheral arterial disease. Thus,
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there could be some association between H pylori infection
and platelet function. The aim of this study was to explore
the relation between H pylori serology status and platelet
activation and endothelial injury in patients with intermit-
tent claudication.
METHODS
Subject selection. Participants to the study were re-
cruited from patients referred to the Vascular Unit, Aber-
deen Royal Infirmary. Patients were eligible for inclusion if
they had symptoms of lifestyle-limiting intermittent calf
claudication and supportive findings on clinical examina-
tion and noninvasive laboratory investigations of peripheral
vascular disease (Table I). Patients were excluded if their
hemoglobin was less than 100 g/L; platelet count less than
150 109/L; creatinine more than twice the upper limit of
normal; aspartate aminotransferase, alkaline phosphatase,
or gamma glutamyl transferase more than three times the
upper limit of normal; and body mass index exceeded 33.
Patients with a history of hematologic malignancy; acute
illness unrelated to peripheral arterial disease within 14
days; transfusion of whole blood within 14 days; known or
suspected alcohol or drug abuse; or on warfarin, steroids, or
clopidogrel were also excluded. All patients were receiving
aspirin when their blood was sampled. A total of 125
patients admitted between March 2002 and February 2003
for diagnostic angiography with a view to angioplasty had
blood sampled for platelet activation studies, von Wille-
brand factor (vWF), and H pylori serology.
The Carstairs Deprivation Score19 was calculated for all
patients as a measure of socioeconomic status. This score is
based on postcode (United Kingdom zipcode) and runs
from 1 (highest socioeconomic status) to 7 (most de-
prived).
Informed consent was obtained from each subject, and
full ethical approval for the study was sought and granted
by the Grampian Research Ethics Committee.
Sample collection. Blood samples were collected us-
ing a 21G needle inserted into an antecubital vein with a
blood pressure cuff applied to the upper arm. The cuff was
removed once the first trickle of blood appeared into the
first of two 1:10 3.2% sodium citrate Vacutainers. For
measurement of platelet activation markers, 50 L blood
was immediately transferred from the second sodium ci-
trate container using a micropipette and diluted in 450 L
HEPES Mg buffer (10 mol/L HEPES, 145 mol/L NaCl,
5 mol/L KCl, 1 mol/L MgSO4, pH 7.4). Blood (3 mL)
was also collected into a serum separator Vacutainer for H
pylori serology.
Platelet activation markers. Platelet P-selectin ex-
pression and fibrinogen binding were measured by using a
whole blood flow cytometric technique as a measure of the
degree of platelet activation. P-selectin is a granule mem-
brane glycoprotein that in resting platelets is found in the
membrane of alpha granules.20 After platelet stimulation, a
release reaction from the granules occurs, and P-selectin is
transferred to the plasma membrane through membrane
fusion21 A P-selectin–specific monoclonal antibody binds
only to activated degranulated platelets. By binding a fluo-
rochrome dye to this antibody, flow cytometric analysis can
identify those platelets in the population that are activated.
Platelet activation also causes a transformation of the sur-
face glycoprotein (GP) IIb/IIIa from an inactive into an
active state which allows ligand binding.22-24 Through
distinct amino acid sequences fibrinogen is bound to
GPIIb/IIIa.25 With the use of a labeled-specific antifi-
brinogen antibody, platelet fibrinogen binding can be reli-
ably measured with flow cytometry26 as a marker of platelet
activation.
The method of analysis for estimation of platelet acti-
vation was adapted from that described previously.2 Sam-
ples were treated in a standardized manner within 1 hour of
collection as follows: 40-L aliquots of whole blood in
HEPES Mg buffer were incubated with monoclonal anti-
bodies for 20 minutes at room temperature in the dark.
Platelets were labeled with fluorescein isothiocyanate
(FITC)-conjugated anti-CD61 (Dako, Glostrup, Den-
mark), which binds to GPIIIa. P-selectin expression was
measured by using dual staining with FITC–anti-CD61
and phycoerythrin (PE)-conjugated anti-CD62P (Immu-
notech, Marseilles, France). Fibrinogen binding was mea-
sured by single-color flow cytometry with the use of FITC-
conjugated rabbit polyclonal antihuman fibrinogen
antibody (Dako). An optimal final concentration of 2
ng/L of each antibody was used. Reactions were stopped
by the addition of 1 mL phosphate-buffered saline (PBS).
Samples were analyzed within 4 hours of preparation with
the use of a Coulter XL-MCL flow cytometer (Coulter
Electronics, Luton, United Kingdom). Platelets were gated
Table I. Characteristics of patients with negative and
positive H pylori status
H pylori
positive
n  62
H pylori
negative
n  56
Sex ratio M:F 46:16 45:11
Mean age (y) 67 64
Mean ankle-brachial pressure index 0.69 0.71
Smoking
Current smoker 21 18
Ex-smoker  1 y 8 10
Ex-smoker  1 y 28 25
Never smoked 5 3
Diabetes, (%) 7 (11) 14 (25)
Mean serum cholesterol 4.82 4.85
Fibrinogen, mmol/L 3.57 3.62
Platelet count, 109/L 261 266
Body mass index, kg/m2 25.7 26.2
Carstair Deprivation Score (%)
1 (most affluent) 2 (3.2) 4 (7.1)
2 16 (25.8) 8 (14.2)
3 20 (32.3) 12 (21.4)
4 15 (24.2) 16 (28.6)
5 5 (8.1) 13 (23.2)
6 2 (3.2) 0 (0)
7 (most deprived) 0 (0) 0 (0)
Missing 2 (3.2) 3 (5.4)
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by their side and forward light scatter characteristics and
enclosed in an electronic bitmap. List-mode data were
stored and processed with the use of a personal computer
and SYSTEM II software version 1.0 (Coulter Electronics)
and converted to scatter plots and histograms. Ten thou-
sand events were analyzed for fluorescence, and the results
were expressed as the percentage of platelets positive for
P-selectin and binding fibrinogen. Mean cell fluorescence
as a measure of the average density of antibody binding per
platelet was recorded. Basal activation status was assessed in
resting samples and platelet reactivity after incubation with
adenosine diphosphate (ADP) at a final concentration of 1
 105 mol/L for 5 minutes (Sigma, St Louis, Mo). The
flow cytometer was aligned daily with Flowcheck and Im-
munobrite beads (Coulter Electronics) to calibrate light
scatter and fluorescence parameters, respectively. The flow
cell was cleaned thoroughly between individual subject
samples to exclude carry-over of platelets to subsequent
analyses with the use of Coulter Clenz cleansing solution
(Coulter). Murine FITC- and PE-conjugated isotype con-
trols (Becton Dickinson Canada Inc, Oakville, Ontario,
Canada) were used to adjust for nonspecific antibody bind-
ing.
Helicobacter pylori serology. H pylori serology was
determined by using an enzyme-linked immunosorbent
assay (ELISA) kit for immunoglobulin G antibody to H
pylori (Premier; Meridian Diagnostics Inc, Milano, Italy).
This assay was performed at the microbiology laboratory at
Aberdeen Royal Infirmary. In a study comparing six com-
mercial kits for H pylori detection, McNulty et al27 found
that Premier ELISA kit used in this study gave the best
overall results and was the easiest to perform. The sensitiv-
ity was 97% and the specificity was 85%. The negative
predictive value was 98% and the positive predictive value
was 83% when compared against the reference standard of
antral biopsy urease test, culture, and histopathology. This
test is a qualitative test and only provides a positive, nega-
tive, or equivocal result. Antibodies against H pylori are
present during infection with the organism but may remain
elevated for at least 12 months after the organism is
eradicated.28
von Willebrand factor levels. The ELISA used for
vWF was an in-house technique previously developed and
validated by the Department of Medicine and Therapeu-
tics, University of Aberdeen. A sandwich technique using
anti-vWF antibody (A0082; Dako) was used.
Statistical analysis. Calculations were performed with
the use of SPSS for Windows version 10.0 statistical soft-
ware (SPSS, Chicago, Ill). Differences between patients
and control subjects were analyzed by using the Mann-
Whitney U test. P  .05 was considered significant.
RESULTS
Subjects and H pylori serology. Of the 125 patients,
62 patients were found to be seropositive for H pylori
(49.6%), 56 (44.8%) were seronegative, and in 7 patients
(5.6%) the result was equivocal.
Table I shows the baseline characteristics of the patients
with positive and negative H pylori seropositivity as well as
the socioeconomic status according to the Carstairs Depri-
vation Score. There was no difference in Carstairs Depriva-
tion Scores between the two groups (P  .22).
P-selectin expression. Median P-selectin expression
was found to be significantly higher in patients who were H
pylori positive (0.815%; range, 0.96%-2.18%) compared
with those who were negative (0.65%; range, 0.2%-4.53%;
P .039). There was no significant difference in P-selectin
mean fluorescence intensity (1.47 vs 1.46; P  .692)
(Table II).
Fibrinogen binding. There was no significant differ-
ence in platelet fibrinogen binding between patients who
were H pylori positive (2.135%) compared with those who
were negative (1.85%; P  .11). There was no significant
difference in bound-fibrinogen mean fluorescence intensity
(2.77 vs 2.28; P  .22) (Table II).
von Willebrand factor. There was no difference be-
tween the two groups in serum vWF levels (196.4 vs 179.4
U/mL; P  .51).
DISCUSSION
The results of this study suggest that platelet activation
is increased in patients with intermittent claudication who
are positive for H pylori compared with those patients who
have no evidence of chronic infection with the microorgan-
ism.
No difference was observed in the level of endothelial
injury as measured by vWF levels between patients positive
and negative for H pylori. vWF is elevated in an array of
clinical situations characterized by vascular damage and has
been used as a marker of endothelial damage, although as a
marker it has poor specificity.29 The patients in the two
groups were practically identical in terms of sex ratio, mean
age, cigarette smoking, severity of disease as measured by
ankle-brachial pressure index, serum cholesterol levels, se-
rum fibrinogen, platelet count, and body mass index. None
of these factors can, therefore, be responsible for the signif-
Table II. Platelet activation markers and vWF according to H pylori status
H pylori positive
n  62
H pylori negative
n  56 P*
Median P-selectin expression, % (range) 0.815 (0.96-2.18) 0.650 (0.2-4.53) .039
Median fibrinogen binding, % (range) 2.135 (0.48-8.37) 1.85 (0.35-8.16) .11
Median vWF, U/mL (range) 196.4 (78.5-365.8) 179.4 (83.8-405.4) .51
*Determined by Mann-Whitney U test.
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icant difference observed in platelet P-selectin expression
between the two groups With regard to socioeconomic
status, the difference between the two groups was not
statistically significant. There was a trend toward lower
socioeconomic class patients in the H pylori–negative
group. This finding is counter to the prevalence in the
general population in whom H pylori positivity is more
common among the lower socioeconomic groups.
There were slightly more diabetic patients in the H
pylori–negative group, although this finding was not statis-
tically significant. Platelet activation has been shown to be
increased in patients with diabetes30; therefore, the in-
creased proportion of diabetic patients in the H pylori–
negative group (25% vs 11%) could have resulted in an
underestimate of the difference in P-selectin expression
between the two groups.
Increased platelet activation in patients with intermit-
tent claudication who are positive for H pylori could be
mediated through endothelial damage. Franceschi et al18
have shown that H pylori–Cag A antibodies cross-react with
both healthy and atherosclerotic blood vessels. H pylori
DNA has been identified within atherosclerotic plaque
from diseased vessels,11-14 and this identification could
imply direct damage by the organism at the site of disease.
Both mechanisms would result in endothelial damage that, in
turn, would explain the higher degree of platelet activation
through various mechanisms such as release of tissue factor
and exposure of subendothelial collagen and vWF. However,
we have failed to identify any difference in vWF levels between
seropositive and seronegative patients which suggests that the
enhanced platelet activation observed in the positive group is
unlikely to be mediated by endothelial injury.
Whether the difference in circulating platelet activation
observed in this study between the two groups is clinically
significant is not clear. However, we have previously dem-
onstrated that the median P-selectin expression in patients
with intermittent claudication is 33% higher than in control
subjects,31 a difference that is of the same order as that
between seropositive and seronegative subjects in the cur-
rent study. Platelet adhesion, activation, and aggregation
play a central role in major vascular events as well as in the
development and progression of atherosclerosis.3 Increased
platelet activation is, therefore, likely to increase the risks
for such events, and this increase is supported by the fact
that antiplatelet drugs, such as aspirin and clopidogrel,
which inhibit platelet activation, have been shown to re-
duce the incidence of such events. Although the prevalence
of H pylori is higher in patients with peripheral arterial
disease compared with control subjects, no studies have
investigated whether H pylori seropositivity carries a signifi-
cantly increased risk of cardiovascular and cerebrovascular
events in this group of patients. Further research would be
required to determine whether eradication of H pylori would
result in a reduction in the levels of platelet activation and,
furthermore, whether this reduction would lead to a lowering
of the higher risk of cardiovascular and cerebrovascular events
observed in patients positive for H pylori. If eradication fails to
reduce platelet activation levels, the alternative strategy would
be to use more effective antiplatelet treatment, which may
involve combinations of drugs, in those patients who are
known to be H pylori positive.
In conclusion, this study has shown that patients with
intermittent claudication who are H pylori positive have
enhanced platelet activation which does not appear to be
mediated through endothelial cell injury.
REFERENCES
1. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen
KH, Schroeder T. Fate in intermittent claudication: Outcome and risk
factors. Br Med J 1986;293:1137-40.
2. Leng GC, Lee AJ, Fowkes FGR, Whiteman M, Dunbar J, Housley E, et
al. Incidence, natural history and cardiovascular events in symptomatic
and asymptomatic peripheral arterial disease in the general population.
Int J Epidemiol 1996;25:1172-81.
3. Cassar K, Bachoo P, Brittenden J. The role of platelets in peripheral
vascular disease. Eur J Vasc Endovasc Surg 2003;25:6-15.
4. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;
340:115-26.
5. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H,
et al. Inflammation in high-grade carotid stenosis: A possible role for
macrophages and T cells in plaques destablization. Stroke 1998;29:
1625-30.
6. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP.
Evaluation of C-reactive protein, an inflammatory marker, and infec-
tious serology as risk factors for coronary artery disease and myocardial
infarction. J Am Coll Cardiol 1998;32:35-41.
7. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: Emerging
mechanistic paradigms. Circulation 1999;100:e20-8.
8. Danesh J, Collins R, Peto R. Chronic infections and coronary heart
disease: Is there a link? Lancet 1997;350:430-6.
9. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA.
Predisposition to atherosclerosis by infection: Role of endothelial dys-
function. Circulation 2002;106:184-90.
10. Bloemenkamp DGM, Mali WPT, Tanis BC, Rosendaal FR, van den
Bosch MAAJ, Kemmeren JM, et al. The relation between Helicobacter
pylori and atherosclerosis cannot be explained by a high homocysteine
concentration. Eur J Clin Invest 2002;32:549-55.
11. Farsak B, Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, et al. Detection
of Chlamydiae pneumoniae and Helicobacter pylori DNA in human
atherosclerotic plaques by PCR. J Clin Microbiol 2000;38:4408-11.
12. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of
Helicobacter pylori in human carotid atherosclerotic plaques. Stroke
2001;32:385-91.
13. Kowalski M. Helicobacter pylori infection in coronary artery disease:
Influence of H pylori eradication on coronary artery lumen after percu-
taneous transluminal coronary angioplasty. J Phys Pharmacol 2001;52:
3-31.
14. Kowalski M, Rees W, Konturek PC, Grove R, Scheffold T, Meixner H,
et al. Detection of Helicobacter pylori specific DNA in human athero-
matous coronary arteries and its association to prior myocardial infarc-
tion and unstable angina. Dig Liver Dis 2002;34:398-402.
15. Markus HS, Mendall MA. Helicobacter pylori infection: A risk factor
for ischaemic cerebrovascular disease and carotid atheroma. J Neurol
Neurosurg Psychiatry 1998;64:104-7.
16. Kahan T, Lundman P, Olsson G, Wendt M. Greater than normal
prevalence of seropositivity for Helicobacter pylori among patients who
have suffered myocardial infarction. Coron Artery Dis 2000;11:523-6.
17. Danesh J, Peto R. Risk factors for coronary heart disease and infection
with Helicobacter pylori: Meta-analysis of 18 studies. BMJ 1998;316:
1130-2.
18. Franceschi F, Sepulveda AR, Gasbarrini A, Pola P, Silveri NG, Gasbar-
rini G, et al. Cross-reactivity of anti-CagA antibodies with vascular wall
antigens: Possible pathogenic link between Helicobacter pylori infec-
tion and atherosclerosis. Cirulation 2002;106:430-4.
19. Carstairs V. Deprivation indices: Their interpretation and use in relation
to health. J Epidemiol Community Health 1995;49(suppl 2):S3-S8.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 3 Cassar et al 563
20. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton
DF. GMP-140, a platelet alpha-granule membrane protein, is also
synthesized by vascular endothelial cells and is localised in Weibel-
Palade bodies. J Clin Invest 1989;84:92-9.
21. McEver RP. Properties of GMP-140, an inducible granule membrane
protein of platelets and endothelium. Blood Cells 1990;16:73-80.
22. Du XP, Plow EF, Frelinger AL III, O’Toole TE, Loftus JC, Ginsberg
MH. Ligands “activate” integrin alpha IIb beta 3 (platelet GPIIb-IIIa).
Cell 1991;65:409-15.
23. Frelinger AL III, Du XP, Plow EF, Ginsberg MH. Monoclonal anti-
bodies to ligand-occupied conforms of integrin alpha IIb beta 3 (gly-
coprotein GpIIb-IIIa) alter receptor affinity, specificity and function.
J Biol Chem 1991;266:17106-12.
24. Sims PJ, Ginsberg MH, Plow EF, Shattil SJ. Effect of platelet activation
on the conformation of the plasma membrane glycoprotein IIa-IIIb
complex. J Biol Chem 1991;266:7345-52.
25. Hawiger J, Timmons S, Kloczewiak. Gamma and alpha chains of human
fibrinogen possess sites reactive with human platelet receptors. Proc
Natl Acad Sci U S A 1982;79:2068-74.
26. Warkentin TE, Powling MJ, Hardisty RM. Measurement of fibrinogen
binding to platelets in whole blood by flow cytometry: A micromethod
for the detection of platelet activation. Br J Haematol 1990;76:387-94.
27. McNulty CAM, Nair P, Watson BE, Uff JS, Valori RM. A comparison
of six commercial kits for Helicobacter pylori detection. Commun Dis
Public Health 1999;2:59-63.
28. Veendaal RA, Pena AS, Meijer JL, Endtz HPN, van der Est MMC, van
Duijn W. Long term surveillance after treatment of Helicobacter pylori
infection. Gut 1991;32:1291-4.
29. Mannucci PM. von Willebrand factor: A marker of endothelial damage?
Arterioscler Thromb Vasc Biol 1998;18:1359-62.
30. Wang ZY, Shi JM, Han Y, Wang YC, Ruan CG. Comparative study of
platelet activation markers in diabetes mellitus patients complicated by
cerebrovascular disease. Blood Coagul Fibrinolysis 2001;12:531-7.
31. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Platelet activation
is increased in peripheral arterial disease. J Vasc Surg 2003;38:99-103.
Submitted May 6, 2003; accepted Sep 9, 2003.
JOURNAL OF VASCULAR SURGERY
March 2004564 Cassar et al
